ImaRx Therapeutics and Royal Philips Electronics N.V. to Collaborate on Potential Treatment for Ischemic Stroke Using Microbubbles and Ultrasound

05 Nov 2007

·www.biospace.com

Collaborate

TUCSON, Ariz. & ANDOVER, Mass.--(BUSINESS WIRE)--ImaRx Therapeutics, Inc. (Nasdaq: IMRX) and Royal Philips Electronics (NYSE: PHG) (AEX: PHI) today announced a research collaboration to evaluate Philips ultrasound technology as part of ImaRx’s SonoLysis™ program to develop new treatment for acute ischemic stroke. Under the agreement, Philips’ Medical Systems division will provide ultrasound devices and technical assistance to ImaRx during laboratory and preclinical studies. The objective of the collaboration is to determine the optimal ultrasound parameters to use with ImaRx’s proprietary MRX-801 microbubble technology.

Organizations

ImaRx Therapeutics, Inc.

Philips ResearchRoyal Philips Electronics NV /Consortium/

Indications

Stroke

Targets

Drugs

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.